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Abstract
Background: Cancer/testis (CT) antigens are protein antigens normally expressed only in germ cells of testis, and yet are
expressed in a proportion of a wide variety of human cancers. CT antigens can elicit spontaneous immune responses in
cancer patients with CT-positive cancers, and CT antigen-based therapeutic cancer vaccine trials are ongoing for ‘‘CT-rich’’
tumors. Although some previous studies found breast cancer to be ‘‘CT-poor’’, our recent analysis identified increased CT
mRNA transcripts in the ER-negative subset of breast cancer.
Methodology/Principal Findings: In this study, we performed a comprehensive immunohistochemical study to investigate
the protein expression of eight CT genes in 454 invasive ductal carcinomas, including 225 ER/PR/HER2-negative (triple-
negative) carcinomas. We found significantly more frequent expression of all eight CT antigens in ER-negative cancers, and
five of them—MAGEA, CT7, NY-ESO-1, CT10 and CT45, were expressed in 12–24% of ER-negative cancers, versus 2–6% of ER-
positive cancers (p,0.001 to 0.003). In comparison, GAGE, SAGE1 and NXF2 were only expressed in 3–5% of ER-negative
and 0–2% of ER-positive cancers. ER-negative cancers were also more likely to simultaneously co-express multiple CT
antigens, with 27% (34/125) of ER-negative, CT-positive tumors expressing three or more CT antigens. HER2 status had no
consistent effect on CT expression, and triple-negative carcinomas showed similar frequencies of MAGEA and NY-ESO-1
expression as ER-negative/HER2-positive carcinomas. More frequent CT expression was also found in tumors with higher
nuclear grade (p,0.001 to p=0.01) and larger in size (.2 cm).
Conclusions/Significance: CT antigens are preferentially expressed in hormone receptor-negative and high-grade breast
cancer. Considering the limited treatment options for ER/PR/HER2 triple-negative breast cancer, the potential of CT-based
immunotherapy should be explored.
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Introduction
Cancer/testis (CT) antigens are protein antigens that are
normally expressed in the germ cells of adult testis and developing
fetal testis and ovary, but not in any other adult tissues.
Examination of various types of human cancer showed CT gene
activation and protein expression in a proportion of human
cancers in a lineage-unrelated fashion [1,2,3,4]. Due to this
restricted pattern of expression, CT antigens are often recognized
by the immune system of cancer patients, and this spontaneous
immunogenicity raises the possibility of their use as therapeutic
cancer vaccine targets. The prototype examples of CT antigens,
MAGE-A [5] and NY-ESO-1 [6], were among the first human
tumor antigens shown to elicit a spontaneous cytotoxic T cell
response in cancer patients[5,7]. Cancer vaccine trials with these
two antigens have demonstrated their capability of inducing
humoral and cell-mediated immune responses in some patients,
and examples of clinical responses have also been documented
[7,8,9,10].
One practical consideration that would determine the potential
utility of CT-based cancer vaccine is the frequency of CT antigen
expression in the specific tumor type being considered, and
cancers of different tissue origin have been shown to differ
significantly in this aspect. Melanoma, ovarian cancer, lung cancer
and bladder cancer are examples of ‘‘CT-rich’’ tumors, whereas
renal cancer, colorectal cancer and lymphoma/leukemia are ‘‘CT-
poor’’, rarely expressing CT antigens [4]. Relatively few studies
have evaluated CT expression in breast cancer, most of them
focusing on the expression of NY-ESO-1 and MAGEA family
[11,12,13,14,15]. The data from these studies were highly
variable, with the reported NY-ESO-1 positive rate between
2.1% to 40% in different immunohistochemical studies and
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this wide variation is not entirely clear but may partially be
explained by the different patient populations that were examined
(see Discussion).
For a given tumor type, the frequency of CT expression is often
dependent upon tumor grade, stage, and histological types.
Tumors of higher grade–e.g. in bladder cancer [16]–and at more
advanced stage–e.g. in melanoma [17] –, more frequently
expressed CT antigens than low grade or early stage tumors. In
lung cancer, squamous cell carcinomas and neuroendocrine
carcinomas more frequently expressed CT antigens than adeno-
carcinomas, demonstrated at both mRNA and at the protein levels
[2]. Consistent with this notion, we recently found significantly
higher frequency of CT mRNA expression in estrogen receptor
(ER) and progesterone receptor (PR) negative breast cancer cell
lines and primary breast cancers, including MAGE-A3, MAGE-
A6, NY-ESO-1, MAGE-A12, LAGE-1, CSAG2 etc [12].
Subsequent immunohistochemical analysis in a series of 153
unselected cases of breast cancer confirmed the more frequent
expression of MAGE-A and NY-ESO-1 protein in ER-negative
tumors, and similar findings were also observed by analyzing 19
cases of ER, PR and HER2 triple-negative breast cancer. Our goal
in the present study was to expand that study and carry out a
comprehensive immunohistochemical analysis of eight CT
antigens in a large cohort of primary ductal breast cancer with
different ER, PR and HER2 status. We found significantly higher
expression rate of all eight CT antigens in the ER negative group
and tumors with high nuclear grade and larger size also showed
more frequent CT expression. These findings indicate that a CT
antigen cancer vaccine, particularly if polyvalent, can potentially
represent an important therapeutic option for patients with ER-
negative breast cancer, including the clinical aggressive triple-
negative subtype for which the treatment options are limited.
Results
Expression characteristics of individual CT antigens
Figure 1 illustrates the typical staining patterns of the eight CT
antigens in breast cancer. Similar to their subcellular localization
in normal testicular germ cells, CT10, CT45, SAGE1 and NXF2
showed nuclear staining in all positive cases, and MAGEA, NY-
ESO-1 and GAGE proteins are present as both nuclear and
cytoplasmic proteins. The relative abundance in the nuclear and
cytoplasmic compartments, however, varied significantly between
individual tumors, as illustrated by NY-ESO-1 (Fig. 2A vs. 2B) and
MAGE-A (Fig. 2C vs. 2D) staining. An exception was CT7, which
is a cytoplasmic protein in normal germ cells but showed mixed
cytoplasmic and nuclear distribution in most positive cases
(Fig. 1C), with either nuclear (Fig. 1C) or cytoplasmic (Fig. 2E)
compartment dominating.
The extent and intensity of CT expression in each positive case
was given a combined numerical score (between 2 to 6, see
Materials and Methods), and the distribution of the scores for
individual CT antigen is shown in Figure 3. The majority of cases
positive for MAGEA, NY-ESO-1, CT45, GAGE, NXF2 or
SAGE1 showed moderate or strong expression, and ,30% of
positive cases showed weak and very focal staining for these CT
antigens. In comparison, CT7 or CT10 positive cases had higher
percentages of weaker positive cases, and 30–35% showed only
weak and very focal (,10%) staining of the tumor cells, as
exemplified in Fig. 2F for CT7. The weaker staining of CT10 in
tumor, however, might be partially due to the lower antibody
strength of anti-CT10 antibody, as CT10 staining in spermato-
gonia was also weaker than other nuclear CT antigens (data not
shown). No statistical significant difference was observed in the
extent/intensity distributions of CT expression between carcino-
mas of different ER status, HER2 status, or other pathological
parameters such as tumor size, nuclear grade or lymph node status
(see below).
Frequency of CT antigen expression
Different CT antigens were expressed at significantly different
frequencies in breast cancer, and this was observed in both Cornell
series and UCSF series (Table 1). Combining both Cornell and
UCSF series, MAGE-A showed most frequent CT expression (77/
454, 17.0%), followed by CT7 (13.7%), NY-ESO-1 (11.2%),
CT45 (10.1%) and CT10 (8.4%). However, since both cohorts
were designed to enrich for ER-negative breast cancers, these
numbers do not represent the expression frequencies in an
unselected breast cancer population. The remaining three CT
antigens–GAGE, SAGE1 and NXF2, were infrequently or rarely
expressed, positive only in 3.5%, 2.2% and 1.8% of the series,
respectively. These three CT antigens were not included in later
comparisons.
ER-positive versus ER-negative tumors
To exclude the possible influence of HER2, the correlation
between ER status and CT expression was first compared using
the 119 ER+HER2- and 225 ER-HER2- (triple-negative) cases in
both Cornell and UCSF cohorts (Figure 4). All five main CT
antigens showed higher expression frequency in the ER-negative
than in the ER-positive group, with statistically significant
differences for all comparisons (p,0.001 for MAGEA, NY-ESO-
1, and CT45, and p,0.005 for CT7, and CT10). Comparison of
all 189 ER+ and 265 ER- tumors irrespective of their HER2 status
led to the same finding (p=0.003 for CT10 and p,0.001 for all
other CTs), as was the comparison between the 225 triple-negative
cases and the 189 ER+ cases (p=0.013 for CT10, 0.006 for CT7
and ,0.001 for MAGE-A, NY-ESO-1 and CT45). For MAGEA,
NY-ESO-1, CT7, CT10 and CT45, the frequency of expression in
all ER-negative (and either HER2+ or HER2-) tumors was 24.5%,
17.7%, 19.2%, 11.7% and 15.8%, respectively. In comparison,
only 2.1% to 6.3% of ER-positive tumors expressed these CT
antigens. The frequencies of CT expression in the triple-negative
(ER-HER2-) carcinomas are similar to the ER-negative group,
being 24.0%, 19.1%, 14.2%, 10.2% and 18.2% for MAGEA, NY-
ESO-1, CT7, CT10 and CT45, respectively.
ER-negative tumors often co-expressed multiple CT
antigens
Breast cancer specimens positive for any one CT antigen were
found to be often positive for additional CT antigens, and this
phenomenon was particularly striking in ER-negative tumors
(Figure 5). Of 265 ER-negative cases, 125 (47.2%) expressed at
least one CT antigen, in contrast to 29 of 189 (15.3%) of ER-
positive cases. Among these 125 CT-positive cases, 34 (27.2%)
expressed three or more of the eight CT antigens examined. In
comparison, 27 of 29 CT-positive ER-positive cases expressed only
one or two CT antigens, and only 2 (6.9%) in the ER-positive
group, significantly less frequent than the ER-negative group
(p=0.026).
HER2-positive versus HER2-negative tumors
CT expression in HER2-positive versus HER2-negative breast
cancers was compared between the ER-HER2+ and ER-HER22
groups to exclude potential influence of ER status, and all HER2+
and all HER22 cases were also compared in parallel (Figure 6).
CT Antigens in ER-Negative Breast Cancer
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ER2HER2+ and ER2HER22 showed similar expression
frequency of MAGEA, NY-ESO-1 and CT10 (p=0.69, 0.26
and 0.11, respectively). In contrast, CT7 showed more frequent
expression in the ER2HER2+ group (47.5% versus 14.2%,
p,0.001), and CT45 were more frequently expressed in the ER-
HER22 group (2.5% versus 18.2%, p=0.009). These differences
in CT7 and CT45 expression remained when all HER2 positive
cases were compared to all HER2 negative cases (p=0.002 and
0.02 for CT7 and CT45, respectively).
Correlation with other pathologic parameters
Correlation between CT expression and nuclear grade, tumor
size and nodal status was evaluated in the Cornell series
irrespective of the ER and HER2 status (Table 2). Breast cancers
with high nuclear grade showed significantly more frequent CT
expression than those with low and intermediate nuclear grades
for all five main CT antigens (p#0.003). Tumors equal to or
greater than 2 cm in size (pT2) also expressed MAGEA, CT7 and
CT10 at higher frequency than tumors of smaller size (p=0.003,
,0.001, and =0.01, respectively). However, no difference was
Figure 1. Immunohistochemical analysis of CT antigen expression in breast cancer. Eight CT antigens were analyzed– MAGEA (A), NY-ESO-
1 (B), CT7 (C), CT10 (D), CT45 (E), GAGE (F), NXF2 (G) and SAGE1 (H). Of these, MAGEA, NY-ESO-1, CT7 and GAGE showed mixed nuclear and
cytoplasmic staining, whereas CT10, CT45, NXF2 and SAGE1 were purely or predominantly nuclear proteins. (Magnifications: 400X).
doi:10.1371/journal.pone.0017876.g001
CT Antigens in ER-Negative Breast Cancer
PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e17876seen between tumors 1–2 cm in size and those that were 1 cm or
less. Lymph node status did not appear to affect CT expression
frequency (lymph node positive versus negative, p=0.17 to 0.83).
Discussion
Invasive ductal carcinoma of the breast is a biologically and
clinically heterogeneous group of carcinomas. While surgical
resection is the main treatment for early disease, adjuvant systemic
treatments are required or recommended in patients with visceral
metastasis, node-positivity, or high-risk node-negative disease, the
last group including all ER-negative carcinoma (NCI treatment
guideline http://www.cancer.gov/cancertopics/treatment/breast).
Hormonaltherapyaloneorhormonaltherapypluschemotherapyis
the usual treatment of choice for ER-positive tumors. For most
patients with ER-negative carcinoma, however, chemotherapy is
the main treatment option. An exception to this scheme is the ER-
negative, HER2-positive subgroup, for which anti-HER2 mono-
clonal antibody is often effective, and this has been used in the
standard care of metastatic HER2-positive breast cancer. Despite
these therapeutic modalities, all ER-negative breast cancers,
including the HER2-positive cases, carry a much poorer prognosis
than ER-positive tumors [18], and additional treatment options are
highly desirable and continuously sought for, particularly for the
subgroup of ER, PR, and HER2 triple-negative carcinoma.
In our previous study [12], we analyzed mRNA transcripts in
breast cancer cell lines and cancer specimens using data sets
derived from massively parallel signature sequencing (MPSS) and
publicly available expression microarray data. These analyses
identified more frequent CT expression in estrogen and
progesterone receptor negative breast cancer, including NY-
ESO-1, LAGE-1, MAGEA, PAGE4 and SSX1. Immunohisto-
chemical analysis, performed for NY-ESO-1 and MAGEA,
confirmed the finding at the protein level and also indicated that
triple-negative breast cancer, in particular, might be a ‘‘CT-rich’’
tumor type. Our present study extends the analysis to encompass
eight CT-X antigens—MAGEA, NY-ESO-1, CT7, CT10, CT45,
GAGE, NXF2 and SAGE1, and showed higher expression rates in
ER negative tumors for all CT antigens. HER2-negative status,
however, does not appear to further increase the CT expression
Figure 2. Variations in cellular and subcellular distributions of CT antigens in breast cancer. (A, B): NY-ESO-1 staining of two ER-negative
carcinomas, showing mixed nuclear and cytoplasmic staining in (A) and pure cytoplasmic staining in (B). (C, D): MAGEA staining of two ER-negative
carcinomas, showing predominantly nuclear (C) and cytoplasmic (D) staining, respectively. (E, F): CT7 staining in two cases, showing diffuse positivity
in .90% of tumor cells in (E), as compared to (F) which showed only scattered positive cells and many tumor cells were negative. (Magnifications:
400X).
doi:10.1371/journal.pone.0017876.g002
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be more frequent in the HER2-positive tumor. The reason for this
difference in CT7 and CT45 is unclear and probably should be
interpreted with caution, as the number of positive cases is
relatively small in some groups.
We found different CT antigens to be significantly different in
their CT expression rate in breast cancer, and GAGE, NXF2 and
SAGE1 were rarely expressed even in the ER-negative group.
This finding is similar to our RNA expression data in lung cancer.
In contrast, GAGE mRNA and protein was expressed in much
higher frequency in malignant melanoma (unpublished data). The
remaining five CT antigens that were studied–MAGEA, NY-
ESO-1, CT7, CT10 and CT45, were expressed in up to 25% of
ER-negative tumors individually, and 47% of ER-negative cancer
expressed at least one CT antigen. This moderate frequency of
expression, in conjunction with the previously demonstrated
spontaneous immuogenicity of these five antigens in cancer
patients [19,20,21,22], suggest this group of CT antigens as
potential cancer vaccines targets for ER-negative breast cancer,
including the triple-negative subgroup. The fact that ER-negative
carcinomas often showed co-expression of multiple CT antigen
indeed would further suggest polyvalent CT vaccine as an
approach that should be explored.
ThefrequencyofCTantigenexpressioninbreastcancerhasonly
beenexaminedina fewpreviousstudies,andthereporteddata were
highly variable [11,12,13,14,15]. By RT-PCR, Sugita et al. [14]
identified NY-ESO-1 mRNA was in 42% of breast cancer, in
comparison to a 13% expressionrate reported by Mischo et al. [13].
However, many of the NY-ESO-1 positive cases in the series of
Sugita et al. contained only low levels of NY-ESO-1 mRNA, and
the authors could only detect NY-ESO-1 protein expression in a
single positive case by immunohistochemistry. Theurillat et al. [15]
studied a largest series of 1355 breast cancers by immunohisto-
chemical analysis in a TMA format, and they similarly observed a
low rate of NY-ESO-1 protein expression, shown in only 2.1% (28/
1355)ofthe cases.This,however,isinsharp contrasttoBandicetal.
[11] who described a 40% NY-ESO-1 positive rate in their study of
recurrent ductal breast cancer, and a high 74% MAGE-A4
positivity was also described in the same study. Several technical
variations could possibly contribute to this wide variation in the
observed CT expression frequency. One was the use of TMA in the
current and some previous studies [12,15] versus whole tissue
sections in others [11,13,14]. Since CT expression in cancer is often
heterogeneous, TMA-based analysis is likely to have a higher false-
negative rate due to sampling errors, and the frequencies obtained
by TMA analysis could be lower for this reason. Other factors that
differed among different studies included the use of different
antibodies and antigen-retrieval techniques. For MAGEA expres-
sion, two monoclonal antibodies were used in these studies, 57B
[11,12,13,14,15] and 6C1 [12], and we have chosen to use 6C1 for
our study as it has been shown to recognize MAGE-A1, -A2, -A3,
-A4, -A6, -A10 and -A12, whereas 57B does not recognize MAGE-
A10 [23] and is not commercially available. In addition to these
technical differences, we believe that a major source of variation is
the different case distribution of ER-positive versus ER-negative
breast cancers in these studies. Since more than 80% of the breast
cancers are ER-positive, a collection of unselected breast cancers
would consist mainly of ER-positive tumors. This would explain the
low (2.1%) NY-ESO-1 positive rate in the large series of Theurillat
et al. [15] which is close to the 2.4% expression rate in the ER-
positivegroupofourCornellseries.Incomparison,65%ofthe cases
(53/81) studied by Bandic et al. were ER-negative tumors, and this
would at least partially account for the higher expression of NY-
ESO-1 and MAGE-A4 proteins in their series of recurrent breast
cancer. However, our 17.7% NY-ESO-1 positivity and 24.5%
MAGEA positivity in the ER-negative group were still substantially
lower than the 40% and 70% positivity rate that they reported,
Figure 3. Distribution of immunohistochemical reactivity percentages among CT-positive breast cancer. The immunoreactivity in each
positive case was given an extent score (1, ,10% cells positive; 2, 10-50% cells positive; 3, .50% cells positive) and an intensity score (1, +;2 ,++;3 ,
+++). A combined score of 2 is considered weak positive, 3 to 4 as moderate, and 5 to 6 as strong positive. Most CT-positive cases showed moderate
to strong reactivity, but CT7 and CT10 had more weak positive cases, see text.
doi:10.1371/journal.pone.0017876.g003
Table 1. Frequency of CT antigen expression in invasive
ductal carcinoma of the breast.
MAGEA
NY-
ESO-1 CT7 CT10 CT45 GAGE NXF2 SAGE1
Cornell 48/289
(16.7%)
25/289
(8.7%)
44/289
(15.2%)
25/289
(8.7%)
26/289
(9.0%)
11/289
(3.8%)
6/289
(2.1%)
6/289
(2.1%)
UCSF 29/165
(17.6%)
26/165
(15.8%)
18/165
(10.9%)
13/165
(7.9%)
20/165
(12.1%)
5/165
(3.0%)
2/165
(1.2%)
4/165
(2.4%)
Total
(No.)
77/454
(17.0%)
51/454
(11.2%)
62/454
(13.7%)
38/454
(8.4%)
46/454
(10.1%)
16/454
(3.5%)
8/454
(1.8%)
10/454
(2.2%)
doi:10.1371/journal.pone.0017876.t001
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breast cancer may also be of higher histological grade in general,
which we also found to correlate with increased CT expression. If
confirmed, it would suggest a possible role for CT-based cancer
vaccine in the treatment of recurrent, both ER+ and ER-, breast
cancers.
Except for CT7, all CT antigens analyzed in this study showed
nuclear and/or cytoplasmic staining patterns identical to their
expression in the testicular germ cells, i.e. MAGEA, NY-ESO-1
and GAGE were present in both nuclear and cytoplasmic
compartments, and CT10, CT45, NXF2 and SAGE1 were
purely nuclear proteins. However, CT7, normally expressed in
the cytoplasm of spermatogonia, was noted to be both nuclear
and cytoplasmic in most tumor cells. This has been previously
reported by Tinguely et al. in multiple myeloma [24].
Intriguingly, myeloma patients with only cytoplasmic CT7
expression were found to have better prognosis than those with
mixed nuclear and cytoplasmic expression, leading the authors to
speculate that nuclear CT7 expression might lead to proliferative
or survival advantages of these neoplastic cells. Whether this
differential subcellular localization has a prognostic influence in
breast cancer is unknown, but no apparent correlation was seen
to the ER and HER2 status, or to the nuclear grade, nodal status
or tumor size (data not shown). In addition to this aberrant
nuclear expression of CT7, MAGEA and NY-ESO-1 also showed
significant difference in their subcellular distribution. Since
MAGEA is a multigene family of more than 10 genes, at least
7 of them recognized by the antibody used, it is likely that some
of the difference of nuclear versus cytoplasmic staining might be
resulted from the expression of different MAGEA gene(s).
However, this explanation cannot account for the difference
observed in NY-ESO-1 staining, and the possible biological basis
and consequence of nuclear versus cytoplasmic NY-ESO-1
expression are unclear at present.
In summary, prior literature suggested breast cancer as a
relatively ‘‘CT-poor’’ tumor type, and CT antigen-based thera-
peutic cancer vaccine trials, e.g. MAGEA3 and NY-ESO-1 trials,
have not been actively pursued in breast cancer for this reason.
Our present study demonstrated higher expression frequencies of
MAGEA, NY-ESO-1 and other CT antigens in the ER-negative
group, including the ER/PR/HER2 triple-negative subgroup, of
invasive ductal carcinoma. Considering the limited treatment
options and the poor prognosis of the triple-negative breast cancer,
further investigations to explore the potential of CT antigen-based
immunotherapy in this patient group is clearly warranted.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki and followed the protocols approved
by the institutional review boards (IRB) of Weill Cornell Medical
College and University of California-San Francisco.
Tissues and tissue microarrays
Formalin-fixed paraffin-embedded breast cancer specimens
used for this study were procured from the Department of
Figure 4. Distribution of CT antigen expression percentages in ER-positive and ER-negative breast cancer. Comparisons were carried
out for each CT antigen between ER+HER2- and ER-HER2- cases and between all ER+ and ER- cases. Significant differences were found for all
comparisons (P,0.005).
doi:10.1371/journal.pone.0017876.g004
Figure 5. Distribution of cases expressing one, two or multiple
CT antigens among all CT–positive cases in percentage.
Significantly greater proportion of ER negative tumors expressed $3
antigens when compared to ER+ tumors (P=0.026).
doi:10.1371/journal.pone.0017876.g005
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Hospital-Weill Cornell Medical Center and the Department of
Pathology at the UCSF Medical Center, following protocols
approved by the IRB of the two institutions.
For the Cornell series, pathology reports from 2006 to 2009 were
searched for cases with the diagnosis of invasive ductal carcinoma.
The ER and HER2 status, available as standard diagnostic work-
up, was recorded. For the purpose of this study, ER-positivity was
defined as at least moderate nuclear ER staining in more than 10%
of tumor cells, and HER2 positivity was documented by either 3+
immunohistochemical staining with anti-HER2 antibody in .30%
of tumor cells, or by a positive fluorescent in-situ hybridization
assay, defined as .2.2 HER2 gene copies per tumor cell.
Hematoxylin and eosin stained slides were reviewed and a
representative block was retrieved from each case for the
construction of tissue microarray (TMA). Final case list selected
for TMA comprised 289 invasive ductal carcinomas, including 163
ER-positive (54 ER+HER2+, 109 ER+HER2-) and 126 ER-
negative specimens (27 ER-HER2+, 99 ER-HER22). All ER-
HER22 cases were also PR-negative, representing so-called ‘‘triple
negative’’ breast cancer. The tumor size, lymph node status and
nuclear grade were also recorded for all cases. The UCSF series,
identified in a similar fashion from archival materials of 1998–2008,
was obtained to specifically expand the categories of ER/PR/
HER2 triple-negative cases and HER2+ cases. The UCSF series
comprises 165 cases, including 139 ER-negative (13 ER-HER22,
126 ER-HER22) and 26 ER-positive (16 ER+HER2+,1 0
ER+HER22) specimens. For the immunohistochemical analysis,
both Cornell series and the UCSF series were constructed into
TMAs with 0.6 mm and 1.5 mm tissue cores, respectively. In total,
454 breast cancers were evaluated in this study, including 225 ER/
PR/HER2 triple-negative, 119 ER+HER22,7 0E R +HER2+,a n d
40 ER-HER2+ ductal breast carciniomas.
Monoclonal and polyclonal antibodies
The antibodies used are summarized in Table 3. Antibodies
against GAGE, SAGE1 and MAGE-A were purchased commer-
cially. GAGE antibody, produced against GAGE-7, is expected to
react with all GAGE gene products due to the extreme high
sequence homology among the GAGE proteins. MAGEA
monoclonal antibody 6C1, produced against MAGE-A1, has
been shown to be broad-reactive for gene products of MAGEA
Figure 6. Distribution of CT antigen expression percentages in HER2 positive and HER2 negative breast cancer. Comparisons were
carried out for each CT antigen between the ER-HER2+ and the ER-HER2- (triple-negative) cases and between all HER2+ and HER2- cases. Significant
differences were found for both comparisons for CT7 and CT45 only (P#0.01), with CT7 more frequently expressed in HER2-positive tumors, whereas
CT45 more frequently in HER2-negative tumors.
doi:10.1371/journal.pone.0017876.g006
Table 2. Correlations between CT expression and clinicopathological parameters.
MAGEA NY-ESO-1 CT7 CT10 CT45
Nuclear grade
1–2 6/141(4.3%) 5/141(3.5%) 7/141(5.0%) 6/141(4.3%) 5/141(3.5%)
3 42/146(28.8%) 20/146(13.7%) 37/146(25.3%) 19/146(13.0%) 21/146(14.4%)
P Value ,0.001 0.003 ,0.001 0.01 0.002
Tumor size
#2 cm 22/193(11.3%) 13/193(6.7%) 17/193(8.8%) 10/193(5.2%) 17/193(8.8%)
.2 cm 24/93(26%) 11/93(11.8%) 26/93(28.0%) 14/93(15.1%) 8/93(8.6%)
P Value 0.003 0.17 ,0.001 0.01 1
Lymph node
Positive 12/98(12.2%) 7/98(7.1%) 18/98(18.4%) 7/98(7.1%) 8/98(8.2%)
Negative 32/167(19.2%) 15/167(9.0%) 24/167(14.4%) 14/167(8.4%) 16/167(9.6%)
P Value 0.172 0.653 0.39 0.82 0.83
doi:10.1371/journal.pone.0017876.t002
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A12 protein [23].
Antibodies against the other CT-X antigens NY-ESO-1, CT7,
CT10, CT45 and NXF2 were produced and characterized in our
laboratory. Antibodies against NY-ESO-1, CT7, CT10 and CT45
have been previously described [25,26,27,28]. For generating
NXF2 monoclonal antibodies, full-length NXF2 cDNA sequence
was cloned into prokaryotic expression vector pQE30 (Qiagen),
and subsequent induction of recombinant protein synthesis and
purification by Ni
+2 affinity chromatography were performed as
previously described [29]. Mouse monoclonal antibodies were
then produced and characterized following previously described
protocols [25]. The specificity of the anti-NXF2 monoclonal
antibodies was confirmed by ELISA and by positive immunohis-
tochemical staining of spermatogonia in testis and negative
staining using a panel of normal adult tissues (data not shown).
Immunohistochemical analysis
Immunohistochemical (IHC) analysis was performed on forma-
lin-fixed paraffin-embedded tissues. Five mm sections of TMA on
coated slides were deparaffinized, rehydrated and treated in H2O2
to block the endogenous peroxidase activity. The sections were
then subjected to antigen retrieval by autoclaving for 15 minutes in
10 mM citrate buffer, pH 6.0. The sections were incubated with
the primary antibody for one hour at room temperature, followed
by detection using DAKO Envision+ horseradish peroxidase
mouse (or rabbit) detection system (DakoCytomation) and DAB as
the chromogen. The slides were counterstained with hematoxylin
and evaluated. Any staining on cancer cells is regarded as positive,
and the immunoreactive intensity was recorded as + to +++ (and a
numeric score of 1 to 3). The heterogeneity of staining was also
recorded as very focal (,10% of tumor cells), focal (10–50%) and
diffuse (.50%), and a corresponding numeric score of 1 to 3 was
assigned. The two scores were combined, given any positive case a
score of 2 to 6. Three cores of normal adult testis were included in
each TMA block in the Cornell series and served as the positive
control.
Statistical analysis
Differences in the frequency of CT antigen expression in
different groups were examined using Fisher’s exact test.
Multivariable logistic regression was used to adjust for potential
differences in data source. For Cornell series where the other
clinical parameters were recorded, association between CT
antigen expression and each of the clinical parameters were
examined using Fisher’s exact test.
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